Tashatuvango / shutterstock.com

18 April 2017Americas

UC, Berkeley appeals to Federal Circuit in CRISPR patent clash

The University of California (UC), Berkeley and the University of Vienna have appealed against the Patent Trial and Appeal Board's (PTAB) decision in the dispute over CRISPR technology.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Broad Institute takes three lines of attack in CRISPR appeal filing

26 October 2017 The Broad Institute of Harvard and MIT has adopted three major arguments in its response to the University of California, Berkeley’s appeal against a patent finding on the CRISPR technology.

PTAB says Broad's CRISPR patents do not interfere with UC Berkeley's

16 February 2017 The Broad Institute of Harvard and MIT’s patents concerning CRISPR technology do not interfere with patent claims filed by the University of California, Berkeley and the University of Vienna.

More on this story

Broad Institute takes three lines of attack in CRISPR appeal filing

26 October 2017 The Broad Institute of Harvard and MIT has adopted three major arguments in its response to the University of California, Berkeley’s appeal against a patent finding on the CRISPR technology.

PTAB says Broad's CRISPR patents do not interfere with UC Berkeley's

16 February 2017 The Broad Institute of Harvard and MIT’s patents concerning CRISPR technology do not interfere with patent claims filed by the University of California, Berkeley and the University of Vienna.

More on this story

Broad Institute takes three lines of attack in CRISPR appeal filing

26 October 2017 The Broad Institute of Harvard and MIT has adopted three major arguments in its response to the University of California, Berkeley’s appeal against a patent finding on the CRISPR technology.

PTAB says Broad's CRISPR patents do not interfere with UC Berkeley's

16 February 2017 The Broad Institute of Harvard and MIT’s patents concerning CRISPR technology do not interfere with patent claims filed by the University of California, Berkeley and the University of Vienna.

More features

‘We created law’: G1/24 and the creation of the ‘diamond standard’

BMS unit loses cell therapy patent at European Patent Office

Amgen sues Biocon over blockbuster bone drugs as first biosimilars enter market

Lord Justice Birss to become chancellor of the High Court

Bankruptcy judge approves $305m sale of genetics testing company

Sanofi successfully challenges rare disease patent in Europe

Bayer appoints new head of IP

WATCH: Policy direction—where are we now?